PriceTargets.com logo

Estrella Immunopharma - ESLA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $16.00
  • Forecasted Upside: 729.02%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.93 As of 12/4/2025 05:00 PM ET
▲ +0.21 (12.21%)

This chart shows the closing price for ESLA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Estrella Immunopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESLA

Analyst Price Target is $16.00
▲ +729.02% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Estrella Immunopharma in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 729.02% upside from the last price of $1.93.

This chart shows the closing price for ESLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Estrella Immunopharma. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/3/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00
10/31/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/12/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00
5/29/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00
2/18/2025D. Boral CapitalInitiated CoverageBuy ➝ Buy$16.00 ➝ $16.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

-0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Estrella Immunopharma logo
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Read More

Today's Range

Now: $1.93
Low: $1.63
High: $2.05

50 Day Range

MA: $1.92
Low: $1.19
High: $3.05

52 Week Range

Now: $1.93
Low: $0.73
High: $3.15

Volume

182,709 shs

Average Volume

264,708 shs

Market Capitalization

$72.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Estrella Immunopharma?

The following sell-side analysts have issued research reports on Estrella Immunopharma in the last year: D. Boral Capital, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ESLA.

What is the current price target for Estrella Immunopharma?

0 Wall Street analysts have set twelve-month price targets for Estrella Immunopharma in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 729.0%. D. Boral Capital has the highest price target set, predicting ESLA will reach $16.00 in the next twelve months. D. Boral Capital has the lowest price target set, forecasting a price of $16.00 for Estrella Immunopharma in the next year.
View the latest price targets for ESLA.

What is the current consensus analyst rating for Estrella Immunopharma?

Estrella Immunopharma currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ESLA, but not buy more shares or sell existing shares.
View the latest ratings for ESLA.

What other companies compete with Estrella Immunopharma?

Other companies that are similar to Estrella Immunopharma include Prima BioMed, Adherex Technologies, Abeona Therapeutics, Aurora Cannabis and Alpha Teknova. Learn More about companies similar to Estrella Immunopharma.

How do I contact Estrella Immunopharma's investor relations team?

Estrella Immunopharma's physical mailing address is 5858 Horton Street, Suite 170, EmeryVille, CA 94608, United States. The company's listed phone number is 510-318-9098 and its investor relations email address is [email protected]. The official website for Estrella Immunopharma is www.estrellabio.com. Learn More about contacing Estrella Immunopharma investor relations.